2026-03-13
Waiv raises $33M Seed
Paris-based Waiv raised $33M in a Seed round co-led by OTB Ventures and Alpha Intelligence Capital.
Round at a Glance
| Company | Waiv |
| HQ | Paris, France |
| Amount | $33M |
| Round | Seed |
| Date | 2026-03-13 |
| Valuation | Not disclosed |
| Total Disclosed Funding | $33M |
Company Snapshot
Waiv is a Paris-based company developing AI-powered precision testing tools for oncology. The company spun out of Owkin (formerly operating as Owkin Dx) and was founded by CEO Meriem Sefta and co-founder Lionel Guillou. Waiv analyses routine pathology slides and multimodal patient data to identify biomarkers and predict treatment response, with products including RlapsRisk BC for breast cancer relapse prediction, MSIntuit for MSI detection, and BRCAura for gBRCA pre-screening.
Investors in This Round
| Investor | Investor HQ Country | Notes |
|---|---|---|
| OTB Ventures | Poland | Co-lead |
| Alpha Intelligence Capital | Luxembourg | Co-lead |
| Serena Data Ventures | France | |
| Karista | France | |
| SistaFund | France |
Known Cap Table
| Investor | Round(s) | Investor HQ Country |
|---|---|---|
| OTB Ventures | Seed | Poland |
| Alpha Intelligence Capital | Seed | Luxembourg |
| Serena Data Ventures | Seed | France |
| Karista | Seed | France |
| SistaFund | Seed | France |
Total disclosed funding: $33M across 1 round.